Information:
Fel:
ID
13008
Beskrivning
506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00003545
Länk
https://clinicaltrials.gov/show/NCT00003545
Nyckelord
Versioner (1)
- 2016-01-11 2016-01-11 -
Rättsinnehavare
CC BY-NC 3.0
Uppladdad den
11 januari 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Leukemia NCT00003545
Eligibility Leukemia NCT00003545
- StudyEvent: Eligibility
Similar models
Eligibility Leukemia NCT00003545
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
histologically confirmed diagnosis of t-cell acute lymphoblastic leukemia (all) or lymphoblastic lymphoma (lbl)
Item
histologically confirmed diagnosis of t-cell acute lymphoblastic leukemia (all) or lymphoblastic lymphoma (lbl)
boolean
C0023449 (UMLS CUI [1])
C0278721 (UMLS CUI [2])
C0278721 (UMLS CUI [2])
leukemia or lymphoma cells should express at least two of the following cell surface antigens: cd1a, cd2, cd3 (surface or cytoplasmic), cd4, cd5, cd7, and cd8
Item
leukemia or lymphoma cells should express at least two of the following cell surface antigens: cd1a, cd2, cd3 (surface or cytoplasmic), cd4, cd5, cd7, and cd8
boolean
C0003339 (UMLS CUI [1])
leukemia cells should be negative for myeloperoxidase or sudan black b if the only t cell markers present are cd4 and cd7, the leukemic cells should be demonstrated to lack the myeloid markers cd33 and/or cd13
Item
leukemia cells should be negative for myeloperoxidase or sudan black b if the only t cell markers present are cd4 and cd7, the leukemic cells should be demonstrated to lack the myeloid markers cd33 and/or cd13
boolean
C2698399 (UMLS CUI [1])
C0075489 (UMLS CUI [2])
C0003339 (UMLS CUI [3])
C0075489 (UMLS CUI [2])
C0003339 (UMLS CUI [3])
induction
Item
refractory to at least one induction treatment regimen or in first or later relapse after achieving a complete remission
boolean
C3179010 (UMLS CUI [1])
no cns leukemia or lymphoma requiring intrathecal or craniospinal radiotherapy
Item
no cns leukemia or lymphoma requiring intrathecal or craniospinal radiotherapy
boolean
C1269563 (UMLS CUI [1])
age
Item
age: 16 and over
boolean
C0001779 (UMLS CUI [1])
bilirubin
Item
bilirubin no greater than 2 times upper limit of normal (unless due to leukemia)
boolean
C1278039 (UMLS CUI [1])
creatinine clearance
Item
creatinine clearance at least 50 ml/min (unless due to leukemia)
boolean
C0373595 (UMLS CUI [1])
neurologic toxicity
Item
no neurologic toxicity of grade 3 or greater during prior treatment of all/lbl
boolean
C0600688 (UMLS CUI [1])
neuropathy
Item
no preexisting neuropathy of grade 2 or greater regardless of causality
boolean
C0442874 (UMLS CUI [1])
seizure disorder
Item
no history of seizure disorder
boolean
C0036572 (UMLS CUI [1])
not pregnant or nursing
Item
not pregnant or nursing
boolean
C0032961 (UMLS CUI [1])
contraception
Item
fertile patients must use effective contraception
boolean
C0700589 (UMLS CUI [1])
erythropoietin
Item
no concurrent erythropoietin
boolean
C0014822 (UMLS CUI [1])
chemotherapy
Item
no other concurrent chemotherapy
boolean
C0392920 (UMLS CUI [1])
no concurrent dexamethasone or other steroidal antiemetics
Item
no concurrent dexamethasone or other steroidal antiemetics
boolean
C0011777 (UMLS CUI [1])
C0001617 (UMLS CUI [2])
C0001617 (UMLS CUI [2])
hormone therapy
Item
no concurrent hormone therapy, except for non-disease-related conditions
boolean
C0279025 (UMLS CUI [1])